Improved Production Process for Native Outer Membrane Vesicle Vaccine against Neisseria meningitidis

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  van de Waterbeemd, Bas ^a   Zomer, Gijsbert ^a   Kaaijk, Patricia ^a   Ruiterkamp, Nicole ^b   Wijffels, René H ^c   van den Dobbelsteen, Germie P J M ^a   van der Pol, Leo A ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b Bilthoven Biologicals Quality Control   (Netherlands)

^c WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BACTERIAL VACCINE; MEMBRANE PROTEIN; NATIVE OUTER MEMBRANE VESICLE; NATIVE OUTER MEMBRANE VESICLE VACCINE; PHENOL; PORIN A; PRESERVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ASEPSIS; BACTERICIDAL ACTIVITY; CELL VACUOLE; DRUG ACTIVITY; DRUG EFFICACY; DRUG QUALITY; DRUG SAFETY; DRUG STABILITY; ENDOTOXIC ACTIVITY; GRAM NEGATIVE BACTERIUM; INTERMETHOD COMPARISON; NEISSERIA MENINGITIDIS; NONHUMAN; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; ULTRACENTRIFUGATION; VACCINE PRODUCTION;

ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; BATCH CELL CULTURE TECHNIQUES; BIOREACTORS; HUMANS; MENINGOCOCCAL VACCINES; MICE; NEISSERIA MENINGITIDIS; PORINS; QUALITY CONTROL; RABBITS;

MUS; NEGIBACTERIA; NEISSERIA MENINGITIDIS;

EID: 84878601769     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065157     Document Type: Article

References (67)

1. Girard MP, Preziosi MP, Aguado MT, Kieny MP, (2006) A review of vaccine research and development: meningococcal disease. Vaccine 24: 4692-4700.
2. Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, et al. (1991) Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 14: 195-207 discussion 208-110.
3. Bjune G, Hoiby EA, Gronnesby JK, Arnesen O, Fredriksen JH, et al. (1991) Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338: 1093-1096.
4. Thornton V, Lennon D, Rasanathan K, Hallahan J, Oster P, et al. (2006) Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine 24: 1395-1400.
5. Holst J, Martin D, Arnold R, Huergo CC, Oster P, et al. (2009) Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 27Suppl 2: B3-12.
6. Saukkonen K, Leinonen M, Abdillahi H, Poolman JT, (1989) Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine 7: 325-328.
7. Martin DR, Ruijne N, McCallum L, O′Hallahan J, Oster P, (2006) The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol 13: 486-491.
8. van der Ley P, van der Biezen J, Poolman JT, (1995) Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine 13: 401-407.
9. Cartwright K, Morris R, Rumke H, Fox A, Borrow R, et al. (1999) Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 17: 2612-2619.
10. van den Dobbelsteen GP, van Dijken HH, Pillai S, van Alphen L, (2007) Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine 25: 2491-2496.
11. Trotter CL, Ramsay ME, (2007) Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev 31: 101-107.
12. Zollinger WD, Donets MA, Schmiel DH, Pinto VB, Labrie J, et al. (2010) Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine.
13. Urwin R, Russell JE, Thompson EA, Holmes EC, Feavers IM, et al. (2004) Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun 72: 5955-5962.
14. Hou VC, Koeberling O, Welsch JA, Granoff DM, (2005) Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. J Infect Dis 192: 580-590.
15. Findlow J, Borrow R, Snape MD, Dawson T, Holland A, et al. (2010) Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 51: 1127-1137.
16. Snape MD, Dawson T, Oster P, Evans A, John TM, et al. (2010) Immunogenicity of 2 Investigational Serogroup B Meningococcal Vaccines in the First Year of Life: A Randomized Comparative Trial. Pediatr Infect Dis J.
17. Bai X, Findlow J, Borrow R, (2011) Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther 11: 969-985.
18. Zollinger WD, Poolman JT, Maiden MC, (2011) Meningococcal serogroup B vaccines: will they live up to expectations? Expert Rev Vaccines 10: 559-561.
19. Frasch CE, Van Alphen L, Holst J, Poolman J, Rosenqvist E (2001) Meningococcal Vaccines, Methods and Protocols. Totowa, NJ:Humana Press Inc: 81-107.
20. Fredriksen JH, Rosenqvist E, Wedege E, Bryn K, Bjune G, et al. (1991) Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 14: 67-79 discussion 79-80.
21. Claassen I, Meylis J, van der Ley P, Peeters C, Brons H, et al. (1996) Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 14: 1001-1008.
22. van de Waterbeemd B, Streefland M, van der Ley P, Zomer B, van Dijken H, et al. (2010) Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. Vaccine 28: 4810-4816.
23. van der Ley P, Steeghs L, Hamstra HJ, ten Hove J, Zomer B, et al. (2001) Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect Immun 69: 5981-5990.
24. van der Ley P, van den Dobbelsteen G, (2011) Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants. Hum Vaccin 7: 886-890.
25. Kulp A, Kuehn MJ, (2010) Biological functions and biogenesis of secreted bacterial Outer Membrane Vesicles. Annual Review of Microbiology 64: 163-184.
26. Fisseha M, Chen P, Brandt B, Kijek T, Moran E, et al. (2005) Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination. Infect Immun 73: 4070-4080.
27. Koeberling O, Giuntini S, Seubert A, Granoff DM (2008) Meningococcal OMV Vaccines from Mutant Strains Engineered to Express Factor H Binding Proteins from Antigenic Variant Groups 1 and 2. Clin Vaccine Immunol.
28. Kovacs-Simon A, Titball RW, Michell SL, (2010) Lipoproteins of bacterial pathogens. Infect Immun 79: 548-561.
29. Keiser PB, Biggs-Cicatelli S, Moran EE, Schmiel DH, Pinto VB, et al. (2010) A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine.
30. Pinto VB, Moran EE, Cruz F, Wang XM, Fridman A, et al. (2011) An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups. Vaccine.
31. Zollinger WD (2003) Vaccine against gram negative bacteria- US patent: US6,558,677 B2.
32. Pajon R, Fergus AM, Koeberling O, Caugant DA, Granoff DM, (2011) Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development. PLoS Negl Trop Dis 5: e1302.
33. Koeberling O, Seubert A, Santos G, Colaprico A, Ugozzoli M, et al. (2011) Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys. Vaccine 29: 4728-4734.
34. Baart GJ, de Jong G, Philippi M, van't Riet K, van der Pol LA, et al. (2007) Scale-up for bulk production of vaccine against meningococcal disease. Vaccine 25: 6399-6408.
35. van de Waterbeemd B, Streefland M, van Keulen L, van den IJssel J, de Haan A, et al. (2012) Identification and optimization of critical process parameters for the production of NOMV vaccine against Neisseria meningitidis. Vaccine 30: 3683-3690.
36. Kaaijk P, van Straaten I, van de Waterbeemd B, Boot EP, Levels LM, et al. (2013) Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease. Vaccine 31: 1065-1071.
37. RotsNY, KleijneDESafety of a nonavalent meningococcal serogroup B vaccine in healthy adult volunteers in a randomised, controlled, single blind study. 16th International Pathogenic Neisseria Conference, Rotterdam, 7-112 September 2008.
38. de Kleijn E, van Eijndhoven L, Vermont C, Kuipers B, van Dijken H, et al. (2001) Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine. Vaccine 20: 352-358.
39. Van Hemert P, (1980) Strictly aseptic techniques for continuous centrifugation. Antonie van Leeuwenhoek, International Journal of General and Molecular Microbiology 46: 501.
40. Kempken R, Preissmann A, Berthold W, (1995) Clarification of animal cell cultures on a large scale by continuous centrifugation. J Ind Microbiol 14: 52-57.
41. Gorringe A, Vincent P, Halliwell D, Reddin K (2006) Patent WO2006/008504 A1: Stable compositions containing outer membrane vesicles, methods of manufacturing.
42. Arigita C, Jiskoot W, Westdijk J, van Ingen C, Hennink WE, et al. (2004) Stability of mono- and trivalent meningococcal outer membrane vesicle vaccines. Vaccine 22: 629-642.
43. Howson CP, Fineberg HV, (1992) Adverse events following pertussis and rubella vaccines. Summary of a report of the Institute of Medicine. Jama 267: 392-396.
44. van der Maas NA, David S, Kemmeren JM, Vermeer-de Bondt PE, (2007) Safety surveillance in the National Vaccination Programme; fewer adverse events with the DTP-IPV-Hib vaccine after the transition to an acellular pertussis component in 2005. Ned Tijdschr Geneeskd 151: 2732-2737.
45. Luijkx T, van Dijken H, van Els C, van den Dobbelsteen G, (2006) Heterologous prime-boost strategy to overcome weak immunogenicity of two serosubtypes in hexavalent Neisseria meningitidis outer membrane vesicle vaccine. Vaccine 24: 1569-1577.
46. Weynants V, Denoel P, Devos N, Janssens D, Feron C, et al. (2009) Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response. Infect Immun 77: 2084-2093.
47. Roy N, Barman S, Ghosh A, Pal A, Chakraborty K, et al. (2010) Immunogenicity and protective efficacy of Vibrio cholerae outer membrane vesicles in rabbit model. FEMS Immunol Med Microbiol 60: 18-27.
48. McConnell MJ, Rumbo C, Bou G, Pachon J, (2011) Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii. Vaccine 29: 5705-5710.
49. Nieves W, Asakrah S, Qazi O, Brown KA, Kurtz J, et al. (2011) A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection. Vaccine 29: 8381-8389.
50. Roy K, Hamilton DJ, Munson GP, Fleckenstein JM, (2011) Outer membrane vesicles induce immune responses to virulence proteins and protect against colonization by enterotoxigenic Escherichia coli. Clin Vaccine Immunol 18: 1803-1808.
51. Pierson T, Matrakas D, Taylor YU, Manyam G, Morozov VN, et al. (2011) Proteomic characterization and functional analysis of outer membrane vesicles of Francisella novicida suggests possible role in virulence and use as a vaccine. J Proteome Res 10: 954-967.
52. Roberts R, Moreno G, Bottero D, Gaillard ME, Fingermann M, et al. (2008) Outer membrane vesicles as acellular vaccine against pertussis. Vaccine 26: 4639-4646.
53. Collins BS, (2011) Gram-negative outer membrane vesicles in vaccine development. Discov Med 12: 7-15.
54. Kesty NC, Kuehn MJ, (2004) Incorporation of heterologous outer membrane and periplasmic proteins into Escherichia coli outer membrane vesicles. J Biol Chem 279: 2069-2076.
55. Chen DJ, Osterrieder N, Metzger SM, Buckles E, Doody AM, et al. (2010) Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc Natl Acad Sci U S A 107: 3099-3104.
56. Kim SH, Kim KS, Lee SR, Kim E, Kim MS, et al. (2009) Structural modifications of outer membrane vesicles to refine them as vaccine delivery vehicles. Biochim Biophys Acta.
57. Holten E, (1979) Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978. J Clin Microbiol 9: 186-188.
58. Baart GJ, Willemsen M, Khatami E, de Haan A, Zomer B, et al. (2008) Modeling Neisseria meningitidis B metabolism at different specific growth rates. Biotechnol Bioeng 101: 1022-1035.
59. Lugtenberg B, Meijers J, Peters R, van der Hoek P, van Alphen L, (1975) Electrophoretic resolution of the "major outer membrane protein" of Escherichia coli K12 into four bands. FEBS Lett 58: 254-258.
60. Gerhardt P, Murray RGE, Wood WA, Krieg NR (1994) Methods for general and molecular bacteriology. WashingtonDC:American Society for Microbiology.
61. Jantzen E, Bryn K, Bergan T, Bovre K, (1974) Gas chromatography of bacterial whole cell methanolysates; V. Fatty acid composition of Neisseriae and Moraxellae. Acta Pathol Microbiol Scand B Microbiol Immunol 82: 767-779.
62. Welch DF, (1991) Applications of cellular fatty acid analysis. Clin Microbiol Rev 4: 422-438.
63. Westphal O, Jann JK, (1965) Bacterial lipopolysaccharide extraction with phenol-water and further application of the procedure. Methods Carbohydr Chem 5: 83-91.
64. Geurtsen J, Steeghs L, Hamstra HJ, Ten Hove J, de Haan A, et al. (2006) Expression of the lipopolysaccharide-modifying enzymes PagP and PagL modulates the endotoxic activity of Bordetella pertussis. Infect Immun 74: 5574-5585.
65. Wilm M, Mann M, (1996) Analytical properties of the nanoelectrospray ion source. Anal Chem 68: 1-8.
66. Ziegler-Heitbrock HW, Thiel E, Futterer A, Herzog V, Wirtz A, et al. (1988) Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int J Cancer 41: 456-461.
67. Luijkx TA, van Dijken H, Hamstra HJ, Kuipers B, van der Ley P, et al. (2003) Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form. Infect Immun 71: 6367-6371.